I agree Tada that its the ground breaking “newness” of this technology that has the potential to tap on any of the turned backs to encourage them to take a closer look (such as the pharma sales reps you mentioned). If 208 ends up going to market as being ground breaking effective in even 4 of their indications then this won’t be a grand slam (because we all have seen a grand slam), this will be a unicorn.
DND